3 news items
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GOSS
7 May 24
delays in the commencement, enrollment and completion of clinical trials; disruption to our operations from the COVID-19 pandemic, including clinical
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
, enrollment and completion of clinical trials; disruption to our operations from pandemics, including clinical trial delays; the Company's dependence
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
GOSS
5 Mar 24
operations from pandemics, including clinical trial delays; the Company's dependence on third parties in connection with product manufacturing
- Prev
- 1
- Next